TGFB1 and cancer: In respect of the use of drugs with different therapeutic indications, the angiotensin II receptor antagonists losartan and candesartan or the anti-fibrotic pirfenidone, have also proved effective in TGFβ signaling reduction, albeit the molecular mechanisms of this action and their role in cancer treatment are still ignored [146,147].